Profiling Precursor Lipids for Specialized Pro-Resolution Molecules in Platelet-Rich Plasma Following Fish Oil and Aspirin Intake by Turner, Lisa A
Virginia Commonwealth University 
VCU Scholars Compass 
Theses and Dissertations Graduate School 
2017 
Profiling Precursor Lipids for Specialized Pro-Resolution 
Molecules in Platelet-Rich Plasma Following Fish Oil and Aspirin 
Intake 
Lisa A. Turner 
Virginia Commonwealth University 
Follow this and additional works at: https://scholarscompass.vcu.edu/etd 
 Part of the Periodontics and Periodontology Commons 
 
© Lisa A. Turner 
Downloaded from 
https://scholarscompass.vcu.edu/etd/4763 
This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has 
been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. 
For more information, please contact libcompass@vcu.edu. 
  
 
 
 
 
© Lisa A. Turner                 2017 
All Rights Reserved
  
Profiling Precursor Lipids for Specialized Pro-Resolution Molecules in Platelet-Rich 
Plasma Following Fish Oil and Aspirin Intake 
 
 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science 
in Dentistry at Virginia Commonwealth University. 
 
 
By 
 
 
Lisa A. Turner 
BSDH Old Dominion University 2004, MS Old Dominion University 2006,  
DDS Virginia Commonwealth University 2014. 
 
 
Director: Parthasarathy A. Madurantakam 
Assistant Professor, Department of General Practice, 
School of Dentistry 
 
 
Virginia Commonwealth University 
Richmond, Virginia 
May 2017 
ii 
 
Acknowledgment 
 
 
I would like to thank my committee members, Dr. Parthasarathy A. Madurantakam, Dr. 
Dayanjan S Wijesinghe, Dr. Al Best, and Dr. Thomas Waldrop for their mentorship and 
guidance in the development of this research. I would like to thank Nuo Therapeutics for the 
provision of materials and equipment to aide in the success of this study, and finally, I wish to 
express my deepest appreciation to my husband Jerry, and three amazing children, Erin, Emily, 
and Brian, who have supported and encouraged me with unending love and sacrifices throughout 
this journey. 
  
iii 
 
Table of Contents 
Table of Contents ........................................................................................................................... iii 
List of Figures ................................................................................................................................. v 
List of Tables ................................................................................................................................. vi 
Abstract ......................................................................................................................................... vii 
Introduction ..................................................................................................................................... 1 
MATERIALS AND METHODS .................................................................................................... 8 
Protocol ....................................................................................................................................... 8 
Study Design ............................................................................................................................... 8 
Blood draw protocol ................................................................................................................... 9 
Sample preparation for lipid extraction .................................................................................... 10 
Lipid Quantification using LC-MS/MS .................................................................................... 10 
Statistical analysis ..................................................................................................................... 12 
RESULTS ..................................................................................................................................... 14 
Flow of participants .................................................................................................................. 14 
Group differences ...................................................................................................................... 14 
Interaction effect ....................................................................................................................... 14 
iv 
 
Aspirin effect ............................................................................................................................ 14 
EFA effect ................................................................................................................................. 14 
No effect evident ....................................................................................................................... 14 
DISCUSSION ............................................................................................................................... 16 
CONCLUSIONS........................................................................................................................... 19 
Literature cited .............................................................................................................................. 20 
Tables ............................................................................................................................................ 23 
Figures........................................................................................................................................... 26 
Appendix ....................................................................................................................................... 37 
Appendix A: PRP Research Protocol ....................................................................................... 37 
Appendix B: PRP STUDY KEY .............................................................................................. 39 
Appendix C: IRB approval ....................................................................................................... 40 
Appendix D: Bayer aspirin insert ............................................................................................. 44 
Appendix E: Sundown fish oil label ......................................................................................... 45 
Appendix F: Recruitment Flyer ................................................................................................ 46 
Vita ................................................................................................................................................ 47 
  
v 
 
List of Figures 
Figure 1. Platelets and Acute Inflammation ................................................................................. 26 
Figure 2. Specialized Pro-resolving Mediators- Lipoxins and Resolvins ..................................... 27 
Figure 3. Lipoxin biosynthesis and structure ................................................................................ 28 
Figure 4. ω-3 Polyunstaurated Fatty Acids ................................................................................... 29 
Figure 5. PRP Armamentarium ..................................................................................................... 30 
Figure 6. Aurix Centrifuge ............................................................................................................ 31 
Figure 7. Aspiration of PRP after centrifugation .......................................................................... 32 
Figure 8. Addition of Ascorbic Acid to PRP ................................................................................ 33 
Figure 9. Ecosanoid Signaling Pathways ...................................................................................... 34 
Figure 10. Biosynthesis of lipoxin and aspirin-triggered lipoxins ................................................ 35 
Figure 11. Specialized pro-resolving mediators ........................................................................... 36 
 
  
vi 
 
List of Tables 
Table 1. ANCOVA results ............................................................................................................ 23	
Table 2. Four groups ..................................................................................................................... 25	
Table 3. Aspirin differences .......................................................................................................... 25	
 
  
vii 
 
Abstract 
 
 
 
PROFILING PRECURSOR LIPIDS FOR SPECIALIZED PRO-RESOLUTION MOLECULES 
IN PLATELET-RICH PLASMA FOLLOWING FISH OIL AND ASPIRIN INTAKE  
 
 by 
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in Dentistry at Virginia Commonwealth University. 
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Background: Unfavorable outcomes following periodontal surgeries can be attributed to 
impaired resolution mechanisms likely due to decreased levels of specialized pro-resolution 
molecules (SPM). The current study investigates if SPM substrate pools in platelet-rich plasma 
preparations (PRP) can be increased by essential fatty acid (EFA) and / or aspirin 
viii 
 
supplementation. Methods: Nineteen healthy volunteers were randomly assigned to take i) 
aspirin; ii) EFA; iii) aspirin and EFA. Four hours after intake, the lipid precursor pools in PRP 
were quantified using combined Liquid Chromatography tandem mass spectrometry (LC-
MS/MS) and the data statistically analyzed using ANCOVA. Results: Of the 77 metabolites 
screened, only FFA (18:3) showed a significant interaction effect (p=0.019).  By itself, neither 
EFA (p>0.9) nor aspirin (p>0.4) showed any difference (P>0.4). Multiple comparisons could not 
identify the differences between groups. Conclusions:  There is inadequate data to support oral 
supplementation of EFA and /or aspirin to increase SPM levels in PRP. 
 
Keywords: Platelet-rich plasma, specialized pro-resolution molecules, mass spectrometry, 
precursor lipids, fish oil, aspirin. 
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Introduction 
 
Disease Burden: Periodontitis is a chronic inflammatory disease initiated by bacterial biofilms 
that naturally form on the teeth that has been shown to be associated with a variety of systemic 
diseases including arthritis, Type II diabetes, preeclampsia, conditions associated with preterm 
low birth weight, and cardiovascular diseases (1). In addition to this link to the systemic diseases, 
chronic periodontitis by itself is the most prevalent disease affecting almost half of the US adult 
population (2).  
Inflammation in Periodontal Disease: Current molecular basis of the pathogenesis indicates that 
bacteria are necessary, but not always sufficient to produce disease (3) and the tissue destruction 
is a result of exaggerated host inflammatory response to the biofilm. The alveolar bone 
destruction and clinical attachment loss associated with the progression of the diseases is 
associated with impaired resolution of bacteria-initiated inflammation. 
Normal Evolution of Inflammatory Process: Following injury of healthy tissue, a predictable 
progression of physiologic events unfolds that can be divided into the phases of inflammation, 
proliferation, and maturation. Each phase is characterized by the sequential elaboration of 
distinctive cytokines by specific cells. While PMNs drive the acute inflammatory phase, 
myofibroblasts and macrophages control repair and regeneration that ultimately results in 
resolution of inflammation.  
In the second stage of the inflammatory phase, leukocytes supplant platelets as the 
dominant cell type, attracted by chemotaxis. White blood cells (WBCs) are the predominant cells 
for the first 3 days after wounding; their numbers peak at approximately 48 hours. 
Polymorphonucleocytes (PMNs) are the first to begin bactericidal activities using inflammatory 
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mediators and oxygen free radical metabolites. However, normal wound healing can occur 
without PMNs. Another leukocyte, the helper T cell, elaborates interleukin-2 (IL–2). IL-2 
promotes further T cell proliferation to augment the immunogenic response to injury. 
As PMN leukocytes begin to wane after 24-36 hours, circulating monocytes enter the 
wound and mature into tissue macrophages. These cells debride the wound on the microscopic 
level and produce a wide variety of important substances, such as IL-1 and basic fibroblast 
growth factor (bFGF). IL-1 stimulates the proliferation of inflammatory cells and promotes 
angiogenesis through endothelial cell replication. bFGF is a chemotactic and mitogenic factor for 
fibroblasts and endothelial cells. Unlike PMNs, macrophage depletion severely impairs wound 
healing, as debridement, fibroblast proliferation, and angiogenesis all diminish. 
Toward the end of the inflammatory cycle, the evolving milieu of eicosanoids in the 
wound interact with the cell types present, resulting in fibroblast synthesis of collagen and 
ground substance (from increased ratio of PGF2α to PGE2). Additionally, the macrophage-
derived growth factors are now at optimal levels, strongly influencing the influx of fibroblasts 
and then keratinocytes and endothelial cells into the wound. As mononuclear cells continue to 
replace WBCs and macrophages, the proliferative phase begins. 
While complete resolution of an acute inflammatory response and return to homeostasis 
are key processes in maintaining good health, sustained, non-resolving inflammation can lead to 
fibrosis and loss of function (Figure 1). The key event in this process is the triggering of 
apoptosis in leucocytes and their subsequent clearance from the site of inflammation by 
macrophages. It has been shown that continued presence of PMNs is a major cause of non-
resolution of inflammation (4).   
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Injury to vascular tissue initiates the extrinsic coagulation cascade that results in the 
formation of a fibrin plug to achieve hemostasis. This plug acts as a lattice for the aggregation of 
platelets, the most common and “signature” cell type of the early inflammatory phase. 
Platelets elaborate a number of proinflammatory substances, including AA metabolites 
such as adenosine diphosphate, tissue growth factor beta (TGF-ß), and platelet-derived growth 
factors (PDGF). These growth factors act on surrounding cells and stimulate chemotaxis of 
neutrophils, monocytes, and fibroblasts to the area of injury.  
Injured tissues, through activated phospholipase A, simultaneously catalyze arachidonic 
acids to produce vasoactive prostaglandins and thromboxane, collectively known as eicosanoids. 
Eicosanoids mediate activity influencing platelet plug formation, vascular permeability, and 
cellular chemotaxis to influence wound healing. 
Arachidonic acid Signaling: 
Originally regarded as just membrane constituents and energy storing molecules, lipids 
are now recognized as potent signaling molecules that regulate a multitude of cellular responses 
via receptor-mediated pathways, including cell growth and death, and inflammation/infection. 
AA, a 20-carbon fatty acid is the main eicosanoid precursor and is a basic constituent of all cells. 
While it is not freely available, AA is released from membrane phospholipid stores through the 
activity of several phospholipase enzymes (predominantly PLA2), which are activated by various 
exogenous stimuli including injury. Once in the cytosol, AA can be metabolized via three 
principal pathways to form an important family of oxygenated products, collectively termed 
eicosanoids that are released from the source cell and act at nanomolar concentrations in an 
autocrine/paracrine manner on target cells. Included in this family are prostaglandins (PGs) and 
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thromboxane (collectively termed prostanoids), formed by cyclooxygenase (COX); leukotrienes 
(LTs) and lipoxins (LXs) by lipoxygenases (LOX) (5) (Figure 2).  
Lipoxins (LX) are trihydroxy-products derived from arachidonic acid (AA) through the 
cooperative interaction of diverse cell types in the inflammatory milieu- neutrophils, eosinophils, 
monocytes, platelets, and endothelial cells. The dense clustering of different cell types presents a 
unique situation for lipid handling. In contrast to the synthesis of protein mediators (e.g., 
cytokines), lipid mediators can be produced along enzyme pathways that involve multiple cells, 
in a process known as transcellular biosynthesis (Figure 3). Under the action of cytosolic 
phospholipase A, membrane AA is immediately secreted into the extracellular milieu, where it is 
taken up and used by nearby cells. In this way, the inflamed tissue becomes a specialized organ 
for lipid metabolism, producing the types and amounts of lipid mediators needed to promote or 
resolve inflammation. 
There are two major routes of LX production from AA in humans. The type of 
lipoxygenase that initiates AA oxygenation can distinguish these, and these are distributed 
differently by cell type.  The first pathway involves the insertion of molecular oxygen at C-5 by 
5-lipoxygenase (5-LO) in concert with the 5-LO activating protein (FLAP) to produce 5-
hydroperoxyeicosatetraenoic acid (5-HpETE), which is further metabolized by 5-LO to produce 
the intermediate, leukotriene A (LTA). This pathway is conducted solely by leukocytes, since the 
distribution of 5-LO is largely restricted to these cell types. LTA4 is readily transferred to 
adjacent cells, usually leading to its processing to other LTs (6). However, adherent platelets, via 
12-LO, will convert LTA4, donated by leukocytes, to LXA4 and LXB4.  The second major route 
of LX biosynthesis involves the initial conversion of AA to 15(S)-HpETE by 15-LO. Following 
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secretion, 15(S)-HpETE is taken up by either neutrophils or monocytes and rapidly converted 
through a 5-LO/ FLAP dependent mechanism to LXA4 and LXB4.  
Resolvins (Rv) are endogenous chemical mediators that are biosynthesized from the 
major ω-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), denoted E 
series (RvE) and D series (RvD) resolvins, respectively. Like LX, Rv can be produced through 
transcellular cooperation, initiated by enzymes in epithelial cells and completed by adjacent 
leukocytes. Conceptually, the substrates EPA and DHA are released from membrane 
phospholipids, metabolized in a transcellular fashion, and secreted in amounts sufficient to 
reverse the course of inflammation. Ideally, this must happen throughout the inflamed tissue, at a 
time that appropriately follows the elimination of the insult, which caused the inflammation, 
continuing on to a return to homeostasis.  
 
Omega-3 fatty acids, Aspirin and SPM: Epidemiological, clinical, and animal studies provide 
substantial support that the long chain ω-3 fatty acids from fish and fish oils, eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA) improve outcomes associated with inflammation 
(7). The mechanisms by which ω-3 fatty acids exert their protection are still emerging but likely 
include alterations in cell membrane composition and effects on gene expression and receptors 
regulating signaling (Figure 4). The anti-inflammatory actions of ω-3 fatty acids are, in part, 
related to reduced leukocyte-derived cytokine formation and modulation of eicosanoid synthesis 
(8). As mentioned above, resolution of inflammation is accomplished by SPMs derived from 
EPA and DHA, known as E-series and D-series resolvins, respectively.  
Aspirin irreversibly acetylates cyclooxygenase-2 (COX-2), inhibiting its ability to 
produce prostanoids. However, acetylated COX-2 can metabolize AA to 15(R)-HETE, which 
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may then be processed to the “aspirin-triggered” LX by 5-LO. Thus, epimers of LXA4 and 
LXB4 can be produced following aspirin treatment. Similar to LX, aspirin-triggered Rv epimers 
are produced by the acetylated COX-2/5-LO pathway. 
Clinical studies involving supplementation of omega-3 fatty acids and detection of SPM 
from human plasma samples using targeted liquid chromatography tandem mass spectrometry 
(LC-MS/MS) have showed that the plasma levels of SPMs can be accurately quantified using 
this technology and that these levels were increased within 4 hours of omega-3 and aspirin intake 
(9). In another recent study, healthy volunteers were given ω-3 fatty acid supplements for seven 
days and then randomized to receive aspirin or placebo in addition to ω-3 fatty acids during the 
last two days. The study showed that ω-3 fatty acid supplementation for five days increased 
plasma levels of 18-HEPE, 17-HDHA, 14-HDHA, and RvE1. Aspirin taken in addition to ω-3 
fatty acids did not differentially affect any SPM. However, aspirin significantly reduced the ratio 
of R- to S-isomers of 17-HDHA (10). 
In a trial on 74 patients with chronic renal disease randomized to ω-3 fatty acids or 
coenzyme Q10 (CoQ) for eight weeks, it was found that ω-3 Fatty acids significantly increased 
plasma levels of 18-HEPE, 17-HDHA, and RvD1 while CoQ had no effect on any plasma SPM. 
Regression analysis showed the increase in 18-HEPE and 17-HDHA following ω-3 fatty acids 
was associated with a change in platelet EPA and DHA, respectively (11). 
Patients with metabolic syndrome who started with reduced plasma concentrations of the 
precursors of the E- and D- series resolvins had their plasma E-series resolvins increased 
following ω -3 fatty acid supplementation and the addition of aspirin did not alter any of the 
plasma SPMs in diseased and control subjects (12). 
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Autologous Platelet Concentrates:  Platelets or thrombocytes are one of the important 
components of blood that play very important role in hemostasis, inflammation and regeneration. 
Normal platelet counts in whole blood is in the range of 150,000 to 400,000 per micro-liter. The 
efficacy of platelets is due to degranulation of alpha and dense granules where a variety of 
growth factors responsible for regeneration is stored (13). Autologous platelet concentrates 
(APC) are derived from patients' own blood and are processed to enriched the amount of 
platelets to at least 1,000,000 per micro-liter. The major technique in preparing platelet-rich 
plasma includes centrifuging whole blood to concentrate platelets. Several different systems are 
available for use in preparation of PRP. These have either one or two spin cycles, operate at 
different speeds, may or may not include leukocytes with the platelets, and have different means 
of activating the platelets. All techniques separates autologous blood into platelets, leukocytes, 
erythrocytes, and plasma. 
Such a high concentration of platelets is expected to be a potent source of endogenous 
growth factors and cytokines that stimulate healing of bone and soft tissues (14). It was 
introduced in dentistry by Whitmann and colleagues, who suggested it would enhance surgical 
healing through the activation of platelets and release of growth factors The efficacy of APC has 
be shown in a various clinical studies (15-20).  
Although there are different recipes for generating APC, we are interested in an FDA 
approved technologies that are being used routinely in clinical practice: PRP (platelet-rich 
plasma, Nuo Therapeutics, MD).   
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MATERIALS AND METHODS 
Protocol: 
The clinical study was undertaken after prior approved by the Institutional Review Board of 
Virginia Commonwealth University (Study ID: HM20002473). Informed consent was obtained 
from each participant. All experiments listed in this protocol involve handling of human blood 
and/or blood products and appropriate personal protective equipment need to be worn at all 
times. The waste were considered as biohazard and disposed of according to regulations. The 
protocol for the entire procedure is listed in Appendix A. 
Study Design:  
Sixty study participants were recruited who satisfy the following inclusion/exclusion criteria. 
Inclusion Criteria: 
1. Healthy adults (>18 years of age) 
2. Non-pregnant 
3. Weight > 110 pounds 
Exclusion Criteria: 
1. History of smoking in the past 2 years 
2. Individuals with known medical conditions and currently receiving treatment for the 
same 
3. History of anti-coagulant, immunosuppresive or antibiotic therapy in the last 6 months 
4. History of non-steroidal anti-inflammatory drug use (Advil, Tylenol) in the past 2 days 
or Aspirin in the past 10 days 
5. History of essential fatty acid (fish oil supplement) intake in the past month 
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6. Known allergic to fish oil components or nuts 
Once written informed consent was obtained from the participant, the subject opened a sealed 
envelope to determine the group he/she will fall into. The research coordinator assigned the 
subjects into any one of the four groups with 15 participants each:  
Group A: Control 
Group B: Subjects taking one softgel of fish oil supplement (1400 mg, Sundown 
Naturals, NY) 
Group C: Subjects taking one tablet of Bayer low-dose (81 mg) aspirin 
Group D: Subjects with both EFA supplement (1.4 g) and aspirin (81 mg) 2 hours apart 
Blood draw protocol:  
Each patient had a total of 2 blood draws and the initial draw was done to establish the baseline 
Figure 5). After 4 hours after drug administration, the second blood draw was done. Personnel 
adequately trained in phlebotomy performed the blood draws. At each time, 40 ml of blood was 
collected in heparinized tubes and centrifuged using Aurix PRP system (Nuo Therapeutics) 
(Figure 6). This was unique in that the procedure is a soft spin for 1 minute after which the 
platelet rich plasma fraction was aspirated and mixed with calcium chloride and ascorbic acid 
following manufacturer’s instructions (Figures 7 and 8). After PRP processing, the samples were 
transferred to labeled tubes with participant’s ID number, age, and sex, to protect confidentiality. 
The labeled specimens were immediately stored at -80oC freezer to prevent degradation until 
ready for analysis. When all samples were collected, the samples were thawed and analyzed 
using the protocol described below.  
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Sample preparation for lipid extraction: 
Lipids were extracted from the biological material using a modified Bligh and Dyer method. 
Briefly, to 200μl of PRP 1ml of methanol containing the required internal standards were added 
followed by the addition of 0.5 ml of chloroform. The monophasic mixture thus obtained was 
incubated at 40o Celsius overnight. Depending on the analysis carried out, the extracted lipids 
were either further purified using solid phase extraction or used as is following dilution to 
achieve the target concentration in the linear dynamic range.  
Lipid Quantification using LC-MS/MS: 
These specialized pro-resolving mediators were analyzed using targeted LC MS/MS methods 
using Shimadzu Nexera UPLC and a hybrid triple quadrupole linear ion trap (AB SCIEX 6500), 
or via untargeted analysis using either LC MS/MS or shotgun lipidomics (AB SCIEX 5600). The 
available lipid panel allowed quantification of following lipids: 
FFA(16:1) FFA(16:2) FFA(24:1) 
FFA(18:1)  FFA(18:2) FFA(18:3) 
FFA(20:0) FFA(20:1) FFA(20:3) 
FFA(20:4) FFA(20:5) FFA(22:4) 
FFA(22:5) FFA(22:6) FFA(24:0) 
LPC(14:0) +AcO LPC(16:1) +AcO LPC(16:0) +AcO 
LPC(18:0) +AcO LPC(18:1) +AcO LPC(18:2) +AcO 
LPC(18:3) +AcO LPC(20:0) +AcO LPC(20:1) +AcO 
LPC(20:2) +AcO LPC(20:3) +AcO LPC(20:4) +AcO 
LPC(20:5) +AcO LPC(22:4) +AcO LPC(22:5) +AcO 
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LPC(22:6) +AcO LPE(16:0) LPE(16:1) 
LPE(18:0) LPE(18:1) LPE(18:2) 
LPE(18:3) LPE(20:0) LPE(20:1) 
LPE(20:2) LPE(20:3) LPE(20:4) 
LPE(20:5) LPE(22:4) LPE(22:5) 
LPE(22:6) LPG(14:0) LPG(18:1) 
LPG(18:3) LPG(20:1) LPG(20:3) 
LPG(20:4) LPG(22:4) LPG(22:5) 
LPG(22:6) LPI(16:0) LPI(18:0) 
LPI(18:1) LPI(18:2) LPI(20:3) 
LPI(20:4) LPS(18:0) PE(18:2/20:1) 
PE(P-16:0/16:0) PS(18:2/22:6) SM(14:0) 
SM(16:0) SM(18:0) SM(18:1) 
SM(20:0) SM(20:1) SM(22:0) 
SM(22:1) SM(24:0) SM(24:1) 
SM(26:0) SM(26:1)  
 
where: 
SM=Sphignomyelin 
LPC=Lysophosphotidylcholine 
LPE=Lysophosphatidylethanolamine 
LPG=Lysophosphatidylglycerol 
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LPI=Lysophosphotidylinositol 
LPS-Lysopphosphatidylserine 
PS=Phosphatidylserine 
FFA=Free Fatty Acids 
PE= Phosphatidylethanolamine 
 
The number designation is for the following (XX:Y): 
XX=number of carbon atoms in the acyl chain. Also referred to as the chain length. 
Y=number of double bonds in the acyl chain. 
 
Statistical analysis: 
Participants were randomly assigned to one of four group intervention groups—using a two-by-
two design (EFA=No or Yes and Aspirin=No or Yes) and there was a specimen collection at 
baseline and post-intervention. The statistical method used to analyze this question was an 
analysis of covariance (ANCOVA) with the following effects: Baseline covariate, Aspirin, EFA, 
and the EFA*Aspirin interaction. There are thus three questions of interest. 
• The p-value associated with the Aspirin effect answers this question: Is the post-
intervention mean of the Aspirin=No groups different than the post-intervention mean of 
the Aspirin=Yes groups, after covarying out the patients’ baseline? Question: does 
Aspirin have a simple effect? 
• The p-value associated with the EFA effect answers this question: Is the post-
intervention mean of the EFA=No groups different than the post-intervention mean of the 
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EFA=Yes groups, after covarying out the patients’ baseline? Question: Does EFA have a 
simple effect? 
• The p-value associated with the EFA*Aspirin interaction answers this question: 
Does the effect of EFA differ in the Aspirin=No and Aspirin=Yes groups, after covarying 
out the patients’ baseline. Question: Is the effect of EFA and Aspirin complicated? 
In statistical analysis, the answer to the interaction question is inspected first. And so, the results 
will be reported according to the following patterns:  
• 4 Treatments: In those lipid precursors where there is a significant EFA*Aspirin 
interaction, all possible treatment group differences will be inspected by Tukey’s HSD 
multiple-comparison procedure and the differences summarized.   
• Aspirin: In those lipid precursors where there is no significant interaction, but 
there is a significant Aspirin effect, the two Aspirin groups will be compared. 
• EFA: In those lipid precursors where there is no significant interaction, but there 
is a significant EFA effect, the two EFA groups will be compared. 
• No effect: In those lipid precursors with no significant interaction effects and no 
significant main effects, the lipid precursors will be listed. 
All analyses were performed using SAS software (version 9.4, SAS Institute Inc., Cary NC). 
Statistical significance was declared at alpha = 0.05. (Unfortunately, in this small study) No 
correction for multiple comparisons was applied.  
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RESULTS 
Flow of participants 
Sixty participants were screened and 60 found eligible. For this study, 19 of the participant 
samples were available for analysis. There were 4 participants in group A, 6 in group B, 4 in 
group C, 5 in group D. 
Group differences 
There were 77 SPMs screened in the 19 PRP participants. There was 1 SPM with a significant 
interaction, 6 with an Aspirin effect, 0 with an EFA effect, and 70 with no apparent difference 
between the groups (Table 1). 
Interaction effect 
Only FFA(18:3) showed a significant interaction effect (P=0.019). With this metabolomics there 
was no EFA difference (P>0.9) nor an Aspirin difference (P>0.4). However, the multiple 
comparison procedure was unable to identify which groups were different (Table 2). 
Aspirin effect 
There was an Aspirin-related difference in 6 metabolomics. These are summarized in Table 3. In 
all cases, the no Aspirin groups had a higher level than the Aspirin groups. For instance, in 
FFA(22:4) the difference was -1.76 (P=0.024). 
EFA effect 
No EFA-related effect was observed. 
No effect evident 
There was no difference between the groups found in these lipid precursors: FFA(16:1), 
FFA(16:2), FFA(18:1), FFA(18:2), FFA(20:0), FFA(20:1), FFA(20:3), FFA(20:4), FFA(20:5), 
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FFA(22:5), FFA(22:6), FFA(24:0), LPC(14:0) +AcO, LPC(16:0) +AcO, LPC(16:1) +AcO, 
LPC(18:0) +AcO, LPC(18:1) +AcO, LPC(18:2) +AcO, LPC(18:3) +AcO, LPC(20:0) +AcO, 
LPC(20:1) +AcO, LPC(20:2) +AcO, LPC(20:3) +AcO, LPC(20:4) +AcO, LPC(20:5) +AcO, 
LPC(22:4) +AcO, LPC(22:5) +AcO, LPC(22:6) +AcO, LPE(16:0), LPE(16:1), LPE(18:0), 
LPE(18:1), LPE(18:2), LPE(18:3), LPE(20:0), LPE(20:1), LPE(20:2), LPE(20:3), LPE(20:4), 
LPE(20:5), LPE(22:5), LPG(18:1), LPG(20:1), LPG(20:3), LPG(20:4), LPG(22:4), LPG(22:5), 
LPG(22:6), LPI(16:0), LPI(18:0), LPI(18:1), LPI(18:2), LPI(20:3), LPI(20:4), LPS(18:0), 
PE(18:2/20:1), PE(P-16:0/16:0), PS(18:2/22:6), SM(14:0), SM(16:0), SM(18:0), SM(18:1), 
SM(20:0), SM(20:1), SM(22:0), SM(22:1), SM(24:0), SM(24:1), SM(26:0), SM(26:1). 
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DISCUSSION 
Wound healing as a result of tissue injury is an active process whereas the body must mount an 
inflammatory response in order to recruit cells with the ability to repair the site, yet also have the 
ability to return the body to homeostasis. Failure for this to occur can lead to dysregulated 
healing events where chronic inflammation persists.  Chronic inflammation is known to underlie 
certain pathologic disease conditions including rheumatoid arthritis, diabetes, and periodontitis. 
In periodontal surgery, procedures such as bone augmentation and soft tissue grafts create 
acute tissue trauma, triggering an inflammatory response. Immediate management of the wound 
site can improve both the healing process and patient’s postoperative experience. Better 
knowledge of the active process of the resolution of inflammation and healing will help us 
manage the acute inflammation which occurs after surgery.  
Since the discovery of SPMs, they have been at the forefront of research in medicine. 
SPMs are known to increase in both blood plasma, and platelet concentrates, with the intake of 
EFA and aspirin (9). Their activity at the wound site is linked to an increase in phagocytic 
activity, and limitation of polymorphonuclear (PMN) leukocyte recruitment and PMN related 
tissue damage, which aid in the body’s resolution of inflammation, and return to homeostasis. 
What is less understood are the precursors along these pathways, what impact aspirin and omega 
3 may have on them, and whether manipulation of these precursors would provide a longer 
acting beneficial effect on wound healing when delivered directly to the wound site via PRP.  
In this novel experiment, we examined the effects of aspirin and fish oil on levels of lipid 
precursors to SPMs, in platelet rich plasma. Although aspirin and fish oil have been shown to 
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increase the levels of SPMs, when examined in both whole blood and platelet concentrates, the 
levels of their lipid precursor molecules have never been investigated before now. 
The data presented in this study includes a population of 19 healthy adult participants. 77 
lipid precursor molecules were quantified by analyzing platelet rich plasma, by means of liquid 
chromatography mass spectrometry, which is used to identify lipid mediators and SPMs in blood 
plasma and serum. We found no significant EFA effect, one interaction effect when both aspirin 
and EFA were administered with regard to one lipid precursor, and a significant aspirin effect on 
6 lipid precursors. 
Although EFA has been found to increase the production of SPMs with a 1400mg dose, it 
had no significant effect on the lipid precursor pools analyzed in this study population.  While 
we anticipate, based on previous findings, that an increase in SPMs likely occurred, it is probable 
that their lipid precursors did not have a significant change due to the dose and time examined. It 
is anticipated that a higher dose administered over a longer timeframe would show a change in 
these precursor pools. 
Aspirin showed a significant effect in 6 lipidomics; FFA 22:4, FFA 22:1, LPE 22:4, LPE 
22:6, LPG 14:0, and LPG 18:3. All were significantly decreased compared to baseline values 
after the intake of aspirin. Analysis of these findings indicate both potentially positive and 
negative effects depending on the pathway affected.  
FFA 22:4 and LPE 22:4 are considered Eicosanoids (Figure 9). The Eicosanoid pathway 
has several physiological as well as some pathological effects dependent on which path the 
molecule takes as it competes for enzymes. The effects produced by Eicosanoids range from 
inhibition of the immune response including fever, allergy, and inflammation, to an increase in 
vascular permeability, influence on cell signaling, and impact on the systems controlling blood 
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pressure.  FFA 22:4 and LPE 22:4 are lipid molecules following the omega 6 pathway, and are 
classified as docosatetraenoic acids. These lipid molecules are precursors to arachadonic acid 
20:4, which leads to the production of a group of inflammatory molecules including PGD2, 
PGE2, PGF2, PGI2, TXA4, LTB4, LTC4, LTD4, LTE4 (Figure 10). The effect found in this 
study indicated that FFA 22:4 and LPE 22:4 were both significantly decreased after the 
administration of 81mg aspirin, compared to baseline values. This shows that there were less 
inflammatory lipid precursors present in the PRP four hours after aspirin administration, which is 
a positive finding. This suggests that a single dose of aspirin may have the ability to alter the pro-
inflammatory lipid pathways, and could potentially improve the beneficial clinical effects of PRP 
at the wound site.  
LPE 22:6 was also significantly decreased with the intake of aspirin. This lipid precursor 
belongs to the omega 3 family, docosahexaenoic acid (DHA). It acts as a precursor to the 
production of resolvins and other SPMs.  
LPG 18:3 is found in the Eicosanoid pathway in both the omega-3 and omega-6 families 
as linolenic acid. In the omega-3 pathway, alpha linolenic acid is a precursor to SPMs, and 
provide a beneficial effect at the wound site. In the omega-6 pathway, it exists as gamma 
linolenic acid, which depending on the enzymes present, could lead to either pro-inflammatory 
molecules, or resolving molecules. Our analysis could not differentiate which pathway was 
involved. Further analysis of the same samples is necessary to establish the aspirin effect on LPG 
18:3 
The remaining significant aspirin effects were established with FFA 22:1 and LPG 14:0, 
both of which were not associated with the SPM pathways.  
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CONCLUSIONS 
 
There were 77 lipid precursors screened in the 19 PRP participants. One (FFA 18:3) showed a 
significant interaction effect with EFA and aspirin, 6 (FFA 22:4, FFA 24:1, LPE 22:4, LPE 22:6, 
LPG 14:0, LPG 18:3) showed a significant Aspirin effect, 0 had an EFA effect, and 70 with no 
apparent difference between the groups (Table 1). The aspirin effect significantly lowered 2 pro-
inflammatory lipid precursors along the arachadonic acid pathway, significantly decreased 1 
lipid precursor in the DHA pathway for the production of SPMs, and significantly decreased 
lipid precursors in pathways not examined in this study (Figure 11).  
The decrease in FFA 22:4 and LPE 22:4 along the Eicosanoid pathway after aspirin 
intake has never been reported before in literature. It may indicate the potential for storage of 
anti-inflammatory lipids, which could prove beneficial when delivered directly to a wound site.  
Additional studies using flux are necessary to understand the exact mechanism.  
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Tables 
Table 1. ANCOVA results 
Lipid Aspirin EFA EFA*Aspirin Pre
FFA(16:1) 0.2741 0.8750 0.4837 0.5232
FFA(16:2) 0.4828 0.5352 0.1726 0.9169
FFA(18:1) 0.6542 0.8772 0.5452 0.5158
FFA(18:2) 0.9036 0.3524 0.6694 0.1768
FFA(18:3) 0.4046 0.9382 0.0192 0.0009
FFA(20:0) 0.9448 0.9927 0.9107 0.7822
FFA(20:1) 0.7260 0.7178 0.7905 0.0000
FFA(20:3) 0.6457 0.5138 0.1944 0.0003
FFA(20:4) 0.7651 0.6648 0.9918 0.0340
FFA(20:5) 0.9189 0.0748 0.3669 0.0193
FFA(22:4) 0.0239 0.1069 0.9604 0.0013
FFA(22:5) 0.3841 0.6704 0.1161 0.0812
FFA(22:6) 0.9244 0.8103 0.5083 0.2904
FFA(24:0) 0.2107 0.5694 0.2093 0.0324
FFA(24:1) 0.0316 0.4947 0.9779 0.0835
LPC(14:0) +AcO 0.1797 0.7624 0.7013 0.0005
LPC(16:0) +AcO 0.4191 0.9720 0.6622 0.0146
LPC(16:1) +AcO 0.0815 0.6643 0.6097 0.0605
LPC(18:0) +AcO 0.5049 0.8945 0.3742 0.0010
LPC(18:1) +AcO 0.1556 0.8450 0.9647 0.0005
LPC(18:2) +AcO 0.6149 0.9794 0.7394 0.0237
LPC(18:3) +AcO 0.6488 0.9448 0.8138 0.0921
LPC(20:0) +AcO 0.3974 0.4406 0.1158 0.0061
LPC(20:1) +AcO 0.4651 0.6652 0.4413 0.0005
LPC(20:2) +AcO 0.3255 0.8214 0.7532 0.0014
LPC(20:3) +AcO 0.1869 0.9817 0.6862 0.0003
LPC(20:4) +AcO 0.5228 0.9461 0.9053 0.0000
LPC(20:5) +AcO 0.8977 0.6722 0.2875 0.0000
LPC(22:4) +AcO 0.4128 0.5465 0.6387 0.0000
LPC(22:5) +AcO 0.9904 0.7625 0.9632 0.0024
LPC(22:6) +AcO 0.5431 0.5211 0.9001 0.0001
LPE(16:0) 0.3264 0.4743 0.9943 0.0017
LPE(16:1) 0.0846 0.4208 0.2554 0.0066
LPE(18:0) 0.3448 0.9813 0.5346 0.9986
LPE(18:1) 0.5837 0.9580 0.7282 0.1016
LPE(18:2) 0.6302 0.8545 0.4757 0.7568
LPE(18:3) 0.6011 0.7954 0.7323 0.9697
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Lipid Aspirin EFA EFA*Aspirin Pre
LPE(20:0) 0.3612 0.2652 0.1598 0.1459
LPE(20:1) 0.3531 0.4584 0.5329 0.9008
LPE(20:2) 0.2173 0.3068 0.3653 0.0607
LPE(20:3) 0.0853 0.3173 0.9502 0.2665
LPE(20:4) 0.6830 0.7577 0.9971 0.3740
LPE(20:5) 0.2342 0.9895 0.1916 0.2502
LPE(22:4) 0.0290 0.2471 0.2699 0.0002
LPE(22:5) 0.1809 0.5940 0.5642 0.0173
LPE(22:6) 0.0317 0.9657 0.9147 0.0065
LPG(14:0) 0.0016 0.5852 0.5783 0.0006
LPG(18:1) 0.2968 0.9243 0.8990 0.1895
LPG(18:3) 0.0147 0.2093 0.6615 0.0239
LPG(20:1) 0.5030 0.7315 0.5106 0.5234
LPG(20:3) 0.2290 0.7611 0.3150 0.0000
LPG(20:4) 0.4327 0.0692 0.7333 0.7578
LPG(22:4) 0.2145 0.2642 0.4268 0.8392
LPG(22:5) 0.9277 0.5618 0.6018 0.2460
LPG(22:6) 0.1611 0.8231 0.5060 0.6327
LPI(16:0) 0.1476 0.4716 0.2472 0.6713
LPI(18:0) 0.2423 0.2001 0.7050 0.5871
LPI(18:1) 0.3465 0.4029 0.1726 0.6871
LPI(18:2) 0.8090 0.1554 0.1172 0.4930
LPI(20:3) 0.2537 0.1481 0.0807 0.3021
LPI(20:4) 0.8839 0.0948 0.1660 0.5489
LPS(18:0) 0.6652 0.1706 0.9326 0.0042
PE(18:2/20:1) 0.4848 0.4609 0.1968 0.2271
PE(P-16:0/16:0) 0.5258 0.4904 0.9418 0.5678
PS(18:2/22:6) 0.8976 0.8691 0.9328 0.6368
SM(14:0) 0.2439 0.7025 0.5480 0.0000
SM(16:0) 0.5925 0.6788 0.4774 0.0004
SM(18:0) 0.1883 0.7402 0.4524 0.0000
SM(18:1) 0.1854 0.6193 0.5283 0.0000
SM(20:0) 0.2691 0.8538 0.4408 0.0003
SM(20:1) 0.4557 0.5543 0.5394 0.0000
SM(22:0) 0.2453 0.5186 0.4027 0.0045
SM(22:1) 0.1461 0.7441 0.5753 0.0010
SM(24:0) 0.4200 0.5291 0.4747 0.0040
SM(24:1) 0.2971 0.4216 0.4287 0.0001
SM(26:0) 0.4895 0.8924 0.5890 0.0107
SM(26:1) 0.2290 0.8124 0.4225 0.0001
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Table 2. Four groups 
Label Effects EFA Aspirin Mean 
FFA(18:3) EFA P=0.938 No No 54.44a
Aspirin P=0.405 Yes Yes 52.68a
EFA*Aspirin P=0.019 Yes No 49.72a
    No Yes 47.68a
 
Table 3. Aspirin differences 
Label Difference Means 
FFA(22:4) -1.764 (-3.254 to -0.274) 9.719 no Aspirin  
P=0.024 7.955 Aspirin  
9.529 Baseline 
FFA(24:1) -6.629 (-12.576 to -0.682) 30.237 no Aspirin 
P=0.032 23.608 Aspirin  
26.113 Baseline 
LPE(22:4) -1.644 (-3.092 to -0.196) 3.649 no Aspirin  
P=0.029 2.005 Aspirin  
2.614 Baseline 
LPE(22:6) -1.024 (-1.944 to -0.104) 2.915 no Aspirin  
P=0.032 1.891 Aspirin  
1.754 Baseline 
LPG(14:0) -0.057 (-0.088 to -0.026) 0.137 no Aspirin  
P=0.002 0.080 Aspirin  
0.124 Baseline 
LPG(18:3) -0.052 (-0.091 to -0.012) 0.126 no Aspirin  
P=0.015 0.074 Aspirin  
    0.105 Baseline 
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Figures 
 
Figure 1. Platelets and Acute Inflammation 
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Figure 2. Specialized Pro-resolving Mediators- Lipoxins and Resolvins 
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Figure 3. Lipoxin biosynthesis and structure 
 Source: https://www.caymanchem.com/news/lipoxins-and-resolvins
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Figure 4. ω-3 Polyunstaurated Fatty Acids 
Source: https://www.caymanchem.com/news/measurement-of-lipid-mediators-of-resolution-of-
inflammation. 
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Figure 5.  Armamentarium for PRP preparation 
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Figure 6. Aurix Centrifuge 
Source: www.autologel.com 
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Figure 7. Aspiration of PRP after centrifugation 
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Figure 8. Addition of Ascorbic Acid to PRP 
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Figure 9. Eicosanoid Signaling Pathways 
Source: https://en.wikipedia.org/wiki/Eicosanoid 
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Figure 10. Biosynthesis of lipoxin and aspirin-triggered lipoxins 
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Figure 11. Specialized pro-resolving mediators 
Source: http://ajp.amjpathol.org/cms/attachment/445087/3098691/gr3_lrg.jpg 
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Appendix 
Appendix A: Research Protocol for Preparation of PRP 
 
Before blood draw 
1. Prepare the materials basket which should include: a phlebotomy kit, goggles, 6 pre-
labeled PRP tubes, 3 pre-labeled PRF tubes, 3 5 mL syringes, goggles, 1 stopcock, 1 
blood needle, 3 1 mL syringes with needles, ascorbic acid, calcium chloride, thrombin, 
and 5 glass vials with labels 
2. Use a 5 mL syringe to draw 5 mL of calcium chloride and inject into the thrombin vial. 
Mix and let it sit until ready to use 
3. Load 0.5 mL of ascorbic into a 1 mL syringe 
4. Load 0.5 mL of the calcium chloride and thrombin mixture into the 2 other 1 mL syringes 
and leave for use after obtaining the blood samples 
5. Meet with the subject and have them fill out the screening form 
6. If the subject is eligible, review the participant consent form with the subject and if they 
wish to participate in the study have he/she sign the consent form with you as witness 
7. Write the subjects name onto the data sheet and let them know if they are in group A, B, 
C or D 
8. Inform the subject how to take their medication accordingly 
9. Ask the subject if they are ready for the blood draw or if they would like to schedule for 
another day 
During the blood draw 
1. Bring out the phlebotomy kit which should include: 1 butterfly needle, 6 pre-labeled PRP 
tubes, 3 pre-labeled PRF tubes, gauze, 1 band aid, 1 test tube rack, 1 tourniquet, and 1 
alcohol swab. 
2. Put on gloves and goggles and ask the patient which arm they prefer to get the blood 
drawn from 
3. Wrap the tourniquet tightly around their desired arm and locate the vein you wish to use.  
4. Disinfect the area using the alcohol swab and allow 30 seconds for the area to dry. 
5. Proceed to inject the butterfly needle and draw 8 mL of blood into each PRF tube and 6 
mL into each PRP tube. 
6. Mix the contents of each tube by inverting the tube 5-8 times then place each tube on the 
rack 
7. Remove the tourniquet and place some gauze on the injected area, before removing the 
butterfly needle 
8. Apply pressure with the gauze until the bleeding has stopped or apply a band aid 
9. Thank and discharge the patient, confirming that they will be returning in 4-6 hours 
10. Clean/disinfect the patient area 
After the blood draw 
1. Place 1 of the PRF tubes labeled whole blood into the freezer for storage. Place the 
remaining two PRF tubes in opposite sides of the PRF centrifuge. 
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2. Press the green button and centrifuge for 12 minutes 
3. Place 2 of the PRP tubes labeled whole blood into the freezer for storage 
4. Place the remaining 4 PRP tubes into the PRP centrifuge and centrifuge for 1 minute 
5. Remove the PRP tubes from the centrifuge and use a 5 mL syringe with a blood needle to 
take the top PRP layer from two of the PRP tubes. Repeat for the other 2 PRP tubes. 
6. Place a stopcock on 1 of the 5 mL syringes and attach the ascorbic acid syringe into the 
stopcock to mix with the PRP. Use the chart to determine how much ascorbic acid is 
needed 
7. Transfer the PRP and ascorbic acid into a vial labeled AA + Ca + T 
8. Transfer the PRP from the remaining 5 mL syringe into the vial labeled Ca + T 
9. Release the calcium and thrombin mixture in each of the 1 mL syringes into each vial. 
Use the chart to determine how much calcium and thrombin mixture is needed. 
10. Close the vials and store the samples in the freezer 
11. Remove the 2 PRF tubes from the PRF centrifuge 
12. Place them onto a clean tray and bring out the Xpression kit which should include a tray, 
weight, small dish, scalpel, and tweezers. 
13. Use tweezers to remove the PRF layer from each of the tubes and place them on the 
Xpression tray. Make sure the PRF layers are directly above the small dish. 
14. Use a scalpel to remove the red blood cells. 
15. Place the weight on top of the PRF layers for 30 seconds. 
16. Collect the PRF pellets and place them into separate labeled vials and then collect the 
liquid that is now in the small dish and transfer it into a separate labeled vial. 
17. Store all 3 samples into the freezer 
18. Clean and disinfect the area. 
19. Repeat the protocol when the patient arrives 4-6 hours later. 
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Appendix B: Study key for preparation of PRP before medication taken, and 4 hours after 
medication taken.  
 
Color code for preparation tubes: 
1. WHITE SALIVA 
2. YELLOW PRP: PRP layer extracted after centrifuging 
3. RED PRP-1: PRP layer w/ Calcium + Thrombin 
4. ORANGE PRP-2: PRP layer w/ Calcium + Thrombin + Ascorbic Acid 
5. WHITE SERUM: Serum collected after blood clotted w/o centrifuging 
6. 2 GREEN PRF PLUG: PRF plug collected after centrifuging and excision 
7. BLUE PRF SN: Supernatant collected after PRF plug was made 
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Appendix C: IRB approval and Consent form 
This Box for IRB Office Use Only – Do Not Delete or ReviseTemplate Rev Date: 6-19-14  
RESEARCH PARTICIPANT INFORMATION AND CONSENT FORM TITLE: Effects 
of Dietary Essential Fatty Acids and Low-dose Aspirin on Specialized  
Pro-resolving Lipid Mediators in Saliva and Autologous Platelet Concentrate Gels  
VCU IRB PROTOCOL NUMBER: HM20002473 INVESTIGATOR: Dr. Parthasarathy 
Madurantakam  
You have been approached by the study doctor or the study staff because you have responded to 
our request to volunteer in the above-mentioned study. If any information in this consent 
document is not clear to you, please feel free to talk to the doctor or the staff involved in the 
study. You may take home an unsigned copy of this consent form to think about or discuss with 
family or friends before making your decision.  
In this consent form, “you” always refers to the research participant.  
PURPOSE OF THE STUDY  
The purpose of this research is to investigate the effects of two commonly available medications: 
fish-oil supplement and baby aspirin, on certain components in blood and saliva necessary for 
wound healing. The information from this research will allow us to determine if taking either 
fish-oil or baby aspirin or both has a beneficial effect on wound healing following surgical 
procedures.  
DESCRIPTION OF THE STUDY  
It has been recently found that presence of adequate amounts of certain kind of fats is critical for 
normal healing after surgery or trauma. Studying the blood levels of these fats was not possible 
because precision instruments were not available. We will use the recent technological advances 
to accurately measure the blood levels of these fats in healthy volunteers after taking EFA (fish-
oil pill) and baby aspirin. In addition, we will explore the potential of using saliva as an alternate 
body fluid to blood to detect these fats.  
Your participation will be limited to one day and we expect to enroll 60 study participants.  
PROCEDURES  
On the day of your scheduled appointment, a member of the research team will meet with you to 
go over the details of the study and the informed consent process. You can use this opportunity 
to ask any questions related to the study; seek more time to decide or may choose to not 
participate in the study.  
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Once you sign the informed consent document, you will have the two procedures done:1. We 
will collect 4 ml of your saliva (that is normally secreted, unstimulated) into a  
plastic tube2. A trained professional will draw 60 ml of your blood (4 tablespoons). This 
amount is  
well within the established safety limits.After the blood draw procedure, you will open a sealed 
envelope to determine which group you would belong. The study has 4 groups based on the type 
of medications the participants will take:  
Group A will not take any pills  
Group B will take one softgel of fish oil supplement (1400 mg, Sundown Naturals, NY) and a 
second blood draw 4 hours later  
Group C will take one tablet of Bayer low-dose (81 mg) aspirin and a second blood draw 4 hours 
later  
Group D will take fish-oil supplement first, low-dose aspirin 2 hours later and a second blood 
draw 2 hours later  
All your saliva and blood samples (baseline and at 4 hours) will be collected in a container that 
contains your study ID number, age, sex and the timing of blood draw (time 0 or time 4hrs). No 
personally identifiable information will be attached to the specimen and no one working in the 
laboratory will know the source.  
RISKS AND DISCOMFORTS  
There are no known risks of saliva collection other than the possibility of you experiencing mild 
discomfort due to dryness of the mouth.  
Possible side effects associated with having blood drawn may involve:  
     Headache  
     Bruising and discoloration at the site  
     Pain  
     Dizziness  
     Prolonged bleeding  
Currently, there is no evidence that aspirin and fish-oil interact to produce any complications. 
 BENEFITS TO YOU AND OTHERS  This is not a treatment study, and you are not 
expected to receive any direct benefits from your participation in the study. The information 
from this research study may lead to better treatment in the future for people who undergo 
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surgery.  PAYMENT FOR PARTICIPATION  In order to compensate for your time and 
procedures you are going through, we will pay you a total sum of $30 by cash. This money will 
be paid at the end of second blood draw and saliva collection. No compensation will be provided 
if you do not come back for the second appointment. In such circumstance, you will no longer be 
considered a study participant and your previously collected sample will not be used in the 
analysis.  ALTERNATIVE  Your alternative is not to participate in the study.   
 
CONFIDENTIALITY  
Potentially identifiable information about you will consist of names, email addresses and phone 
numbers. The investigator, research coordinator and the residents who work on this study will 
have access to this information. At the end of the blood draw procedure, the blood will be 
transferred into a separate container and labeled with a study ID number, your age, sex and the 
time of sample collection (time 0 or time 4 hours). No personally identifiable information will be 
attached to the specimen and hence no one working with the specimen in the laboratory will 
know the source.  
The research coordinator will store your identifiable information and link it to the study ID 
number. This information will be kept separately in a locked research area and only the 
coordinator and the PI will have access to this information. The personal identifiable information 
and the study code will be destroyed at the end of the study while the consent forms will be kept 
for a period of five years from the conclusion of the study in accordance to VCU policies.  
Although results of this research may be presented at meetings or in publications, identifiable 
personal information pertaining to participants will not be disclosed.  
QUESTIONS  
If you have any questions, complaints, or concerns about your participation in this research, 
contact:  
Dr. Parthasarathy Madurantakam  
Assistant ProfessorPhilips Institute, Room 41301101 East Leigh Street, Richmond, VA 
23298 Telephone: (804) 828 9353Email: madurantakap@vcu.edu  
and/or  
Ms. Kimberly Hollaway  
Research Coordinator521 North 11th Street, Richmond, Virginia 23298 Phone: (804) 828-
4553Email: klhollaway@vcu.edu  
The researcher/study staff named above is the best person(s) to call for questions about your 
participation in this study.  
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If you have general questions about your rights as a participant in this or any other research, you 
may contact:  
Office of ResearchVirginia Commonwealth University 800 East Leigh Street, Suite 3000 P.O. 
Box 980568Richmond, VA 23298Telephone: (804) 827-2157  
Contact this number for general questions, concerns, or complaints about research. You may also 
call this number if you cannot reach the research team or if you wish to talk to someone else. 
General information about participation in research studies can also be found at 
http://www.research.vcu.edu/irb/volunteers.htm.  
Do not sign this consent form unless you have had a chance to ask questions and have received 
satisfactory answers to all of your questions.  
CONSENT  
I have been provided with an opportunity to read this consent form carefully. All of the questions 
that I wish to raise concerning this study have been answered.  
By signing this consent form, I have not waived any of the legal rights or benefits, to which I 
otherwise would be entitled. My signature indicates that I freely consent to participate in this 
research study. I will receive a copy of the consent form once I have agreed to participate.  
Participant Name, printed  
Participant Signature Date  
Name of Person Conducting Informed Consent Date Discussion / Witness  
Signature of Person Conducting Informed Consent Date Discussion / Witness  
Principal Investigator Signature (if different from above) Date  
Approved by the VCU IRB on 5/4/2015  
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Appendix D: Aspirin Regimen- Bayer® Low Dose Aspirin 81 mg insert 
 
 
8  
 
 45 
 
Appendix E: Brand of fish oil used in the study 
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Appendix F: Recruitment Flyer 
Virginia Commonwealth University 
Healthy Volunteers Wanted for a Research Study 
Effects of Dietary Essential Fatty Acids and Low-dose Aspirin on Specialized Pro-resolving 
Lipid Mediators in Autologous Platelet Concentrate Gels 
The purpose of this research is to investigate the effects of two commonly available medications: 
fish-oil supplement and baby aspirin, on certain lipid (fat) components of blood necessary for 
wound healing. We will use sophisticated lab methods to accurately measure the blood levels of 
these fats in healthy volunteers after taking EFA (fish-oil pill) and baby aspirin. The information 
from this research will allow us to determine if taking either fish-oil or baby aspirin or both will 
have beneficial effects on wound healing following surgery. The research is conducted under the 
direction of Dr. Parthasarathy Madurantakam, Philips Institute of Oral Health Research, VCU 
School of Dentistry. 
The study will comprise of 60 participants and will involve two blood draws (60 ml each, 
approximately 4 tbsp) following clinically approved protocols, 4 hours apart. Your participation 
in this study will be limited to one half day and you will not be compensated for your 
participation.   
To be eligible, you should be a healthy adult (> 18 years of age and not having any known 
medical condition), non-pregnant and weigh at least 110 lbs. In addition, you will not be eligible 
to participate if you have: 
● History of smoking in the past 2 years 
● History of anti-coagulant, immunosuppresive or antibiotic therapy in the last 6 months 
● History of non-steroidal anti-inflammatory drug use (Advil, Tylenol or Aspirin) in the 
past 1 month 
● History of fish-oil supplement (essential fatty acid) intake in the past month 
● Known allergy to fish-oil components or nuts 
If you are interested and want to participate in this study or if you have any questions, please 
contact  
Kimberly Hollaway at klhollaway@vcu.edu or 804-828-4553 
Dr. Madurantakam at madurantakap@vcu.edu or 804-828-9353 
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Vita 
 
Dr. Lisa Turner was born and raised in Richmond, Virginia. She received a Bachelor of Science 
in Dental Hygiene from Old Dominion University in 2004, a Master of Science in Dental 
Hygiene from Old Dominion University in 2006, and worked as a dental hygienist in private 
practice before attending Virginia Commonwealth University School of Dentistry, where she 
earned a Doctor of Dental Surgery in 2014. She is a member of the American Dental 
Association, Virginia Dental Association, and the American Academy of Periodontology. Dr. 
Turner will graduate from Virginia Commonwealth University with a Master of Science in 
Dentistry, and a Certificate in Periodontics.  
 
 
